The present work is aimed at studying the costs of the treatment scheme with the CIMAvax-EGF® therapeutic vaccine developed and produced by the Center for Molecular Immunology (CIM) and the comparison with the costs of the oncospecific treatments described in the protocol of action for Non-Small Cell Lung Cancer (NSCLC). The scenario selected for the development of the research is the Surgical Clinical Hospital "Hermanos Ameijeiras" (HHA). During the development of the work, the CIM where the vaccine is produced is also characterized and the study of costs is carried out based on the information provided by the HHA. As a result, the costs associated with the treatment of NSCLC by the application of the CIMAvax® vaccine are obtained in comparison with the costs of the oncospecific treatments described in the action protocol, with an increase of $217,600.60. Its economic and clinical impact is demonstrated.